



4050.001100.ST25  
SEQUENCE LISTING

<110> Smythe , Mark Leslie  
Meutermans, Wim Denis Franss

<120> Auxiliary for Amide Bond Formation

<130> 4050.001100

<140> 09/787,840

<141> 2001-07-06

<150> PCT/AU99/00812

<151> 1999-09-24

<150> AU PP6165

<151> 1998-09-25

<160> 43

<170> PatentIn version 3.2

<210> 1

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = HS-(CH<sub>2</sub>)<sub>2</sub>-Tyr

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = Gly-OH

<400> 1

Xaa Arg Phe Xaa

1

<210> 2

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = butyl-Tyr substituted

<220>

<221> MISC\_FEATURE

4050.001100.ST25

<222> (2)..(2)  
<223> Xaa = 2,2,5,7,8-pentamethylchroman-6-sulfonyl-Arg

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Gly WANG resin

<400> 2

Xaa Xaa Phe Xaa  
1

<210> 3  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(5-nitro-2-mercaptobenzyl)-Tyr

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Gly-OH

<400> 3

Xaa Arg Phe Xaa  
1

<210> 4  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = HS-(CH<sub>2</sub>)<sub>2</sub>-Ala

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ala-OH

<400> 4

Xaa Phe Leu Pro Xaa  
1 5

<210> 5  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ala-WANG resin

<400> 5

Ala Phe Leu Pro Xaa  
1 5

<210> 6  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = HS-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Ala-OH

<400> 6

Xaa Leu Pro Xaa  
1

<210> 7  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(2-hydroxy-5-nitrobenzyl)-Ala

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)

4050.001100.ST25

<223> Xaa = Ala-OH

<400> 7

Xaa Phe Leu Pro Xaa  
1 5

<210> 8

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)...(1)

<223> Xaa a= N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>

<221> MISC\_FEATURE

<222> (5)...(5)

<223> Xaa = Ala-OH

<400> 8

Xaa Phe Leu Pro Xaa  
1 5

<210> 9

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 9

Val Ala Gly Phe  
1

<210> 10

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 10

Ala Phe Leu Pro Ala  
1 5

<210> 11

<211> 5

4050.001100.ST25

<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 11

Xaa Leu Pro Ala Ala  
1 5

<210> 12  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-Ala

<400> 12

Xaa Phe Leu Pro Ala  
1 5

<210> 13  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = HS-(CH<sub>2</sub>)<sub>2</sub>-Ala

<400> 13

Xaa Phe Leu Pro Ala  
1 5

<210> 14  
<211> 8  
<212> PRT  
<213> ARTIFICIAL

4050.001100.ST25

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Ala-NH<sub>2</sub>

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> Xaa = Ala-OH

<400> 14

Xaa Leu Pro Xaa Xaa Leu Pro Xaa  
1 5

<210> 15  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 15

Xaa Phe Leu Pro Ala  
1 5

<210> 16  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

4050.001100.ST25

<400> 16

Xaa Phe Leu Pro Ala  
1 5

<210> 17

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 17

Xaa Leu Pro Ala Ala  
1 5

<210> 18

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 18

Xaa Leu Pro Ala Ala  
1 5

<210> 19

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 19

Ala Phe Leu Pro Ala  
1 5

<210> 20

<211> 5

4050.001100.ST25

<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 20

Phe Leu Pro Ala Ala  
1 5

<210> 21  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 21

Tyr Arg Phe Gly  
1

<210> 22  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 22

Xaa Arg Phe Gly  
1

<210> 23  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl) substituted Tyr

<400> 23

Xaa Arg Phe Gly

1

<210> 24  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 24

Tyr Arg Phe Gly  
1

<210> 25  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 25

Leu Tyr Arg Ala Gly  
1 5

<210> 26  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 26

Gly Ala Gly Pro Ala  
1 5

<210> 27  
<211> 10  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 27

Leu Tyr Arg Ala Gly Gly Ala Gly Pro Ala  
1 5 10

<210> 28  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

4050.001100.ST25

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 28

Leu Tyr Arg Ala Phe  
1 5

<210> 29  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 29

Ala Ala Arg His Thr  
1 5

<210> 30  
<211> 10  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 30

Leu Tyr Arg Ala Phe Ala Ala Arg His Thr  
1 5 10

<210> 31  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 31

Phe Leu Pro Ala Ala  
1 5

<210> 32  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 32

Phe Phe Phe Phe

1

<210> 33  
<211> 14  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 33

Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser  
1 5 10

<210> 34  
<211> 16  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 34

Cys Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ala Ser Ser Gly  
1 5 10 15

<210> 35  
<211> 11  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 35

Val Ser Ile Leu Glu Thr Lys Ile Tyr Gly Thr  
1 5 10

<210> 36  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ala-Trityl resin

<400> 36

Ala Phe Leu Pro Xaa  
1 5

<210> 37  
<211> 4  
<212> PRT  
<213> ARTIFICIAL  
  
<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Phe-resin

<400> 37

Val Ala Gly Xaa  
1

<210> 38  
<211> 11  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 38

Thr Gly Tyr Ile Lys Thr Glu Leu Ile Ser Val  
1 5 10

<210> 39  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = H-Ala

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = Ala-OH

<400> 39

Xaa Phe Leu Pro Xaa  
1 5

<210> 40  
<211> 8

4050.001100.ST25

<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Ala-NH<sub>2</sub>

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> Xaa = Ala-NH<sub>2</sub>

<400> 40

Xaa Leu Pro Xaa Xaa Leu Pro Xaa  
1 5

<210> 41  
<211> 8  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa = Ala-OH

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> Xaa = S-(CH<sub>2</sub>)<sub>2</sub>-NH-CH(CH<sub>3</sub>)-CO-Phe

<220>  
<221> MISC\_FEATURE  
<222> (8)..(8)  
<223> Xaa = Ala-OH

<400> 41

Xaa Leu Pro Xaa Xaa Leu Pro Xaa  
1 5

<210> 42  
<211> 5  
<212> PRT  
<213> ARTIFICIAL  
  
<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 42

Xaa Phe Leu Pro Ala  
1 5

<210> 43  
<211> 5  
<212> PRT  
<213> ARTIFICIAL  
  
<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 43

Xaa Phe Leu Pro Ala  
1 5